The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease

The Effects of an Uninterrupted Switch from Donepezil to Galantamine without Dose Titration on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease

Aims: To elucidate the efficacy of galantamine on cognition and behavioral and psychological symptoms of dementia (BPSD) in outpatients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) who have switched from donepezil to galantamine. Materials and Methods: We performed an unint...

Full description

Bibliographic Details
Main Authors:	Shoichi Sasaki, Yoshiharu Horie
Format:	Article
Language:	English
Published:	Karger Publishers 2014-05-01
Series:	Dementia and Geriatric Cognitive Disorders Extra
Subjects:	Alzheimer’s disease Behavioral and psychological symptoms of dementia Donepezil Drug switching Galantamine Mild cognitive impairment
Online Access:	http://www.karger.com/Article/FullText/362871

Similar Items

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
by: Dan-Dan Li, et al.
Published: (2019-05-01)

Comparison of cognitive decline medications of Alzheimer´s disease : Efficacy and safety of Donepezil, Galantamine, Rivastigmine and Memantine
by: Sarwary, Mariam
Published: (2017)

What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink
by: Venexia M. Walker, et al.
Published: (2018-05-01)

Galantamine-memantine combination effective in dementia: Translate to dementia praecox?
by: Maju Mathew Koola, et al.
Published: (2018-06-01)

Efficacy of bacopa monnieri (Brahmi) and Donepezil in Alzheimer's Disease and mild cognitive impairment: A randomized double-blind parallel Phase 2b study
by: Sudesh Prabhakar, et al.
Published: (2020-01-01)

Rate of Conversion from Prodromal Alzheimer's Disease to Alzheimer's Dementia: A Systematic Review of the Literature
by: Alex Ward, et al.
Published: (2013-09-01)

Safety of Cholinesterase Inhibitors and NMDA Receptors Antagonists for the Treatment of Patients with Dementia
by: A. P. Pereverzev, et al.
Published: (2019-12-01)

Effects of Different Administration Protocols on the Plasma Concentration of Donepezil Hydrochloride in Dementia Patients with Stage 5 Chronic Kidney Disease
by: Chika Amano, et al.
Published: (2013-06-01)

Methylphenidate and galantamine in patients with vascular cognitive impairment–the proof-of-principle study STREAM-VCI
by: Jolien F. Leijenaar, et al.
Published: (2020-01-01)

Cognitive Profiles of Patients with Mild Cognitive Impairment or Dementia in Alzheimer's or Parkinson's Disease
by: Helmut Hildebrandt, et al.
Published: (2013-04-01)

Prevalence and Covariates of Elevated Depressive Symptoms in Rural Memory Clinic Patients with Mild Cognitive Impairment or Dementia
by: Julie G. Kosteniuk, et al.
Published: (2014-07-01)

Evaluation of Anosognosia in Alzheimer's Disease Using the Symptoms of Early Dementia-11 Questionnaire (SED-11Q)
by: Yohko Maki, et al.
Published: (2013-10-01)

Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients
by: Zhang N, et al.
Published: (2018-10-01)

Hydroxypropyl Methylcellulose-Based Hydrogel Copolymeric for Controlled Delivery of Galantamine Hydrobromide in Dementia
by: Sidra Bashir, et al.
Published: (2020-10-01)

Pisa syndrome induced by switching of a choline-esterase inhibitor treatment from donepezil to galantamine: a case report
by: Yu Mimura, et al.
Published: (2020-05-01)

Sleep and memory problems: acetylcholine in some neurodegenerative diseases, use of an extended-release formulation of galantamine
by: I V Litvinenko
Published: (2012-06-01)

DONEPEZIL THERAPY OF UNDIFFERENTIATED DEMENTIA IN CLINICAL PRACTICE
by: Y. V. Zhitkova, et al.
Published: (2017-12-01)

Cholinesterase Inhibitors: A population-based assessment of resource utilization for patients with Alzheimer's dementia in Ontario
by: FONG, RAYMOND
Published: (2011)

Subjective Cognitive Impairment Subjects in Our Clinical Practice
by: Sara Garcia-Ptacek, et al.
Published: (2014-11-01)

Anti-dementia medications: Fighting a losing battle?
by: Micov Ana, et al.
Published: (2020-01-01)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
by: Ben Seltzer
Published: (2009-12-01)

Symptoms of Early Dementia-11 Questionnaire (SED-11Q): A Brief Informant-Operated Screening for Dementia
by: Yohko Maki, et al.
Published: (2013-04-01)

Total output and switching in ategory fluency successfully iscriminates Alzheimer's disease from Mild Cognitive Impairment, but not from frontotemporal dementia
by: Siddharth Ramanan, et al.

Clinical Assessment of Alzheimer’s Disease and Response to Donepezil Treatment
by: Serge Gauthier
Published: (2020-12-01)

Influence of the rs1080985 Single Nucleotide Polymorphism of the CYP2D6 Gene and APOE Polymorphism on the Response to Donepezil Treatment in Patients with Alzheimer's Disease in China
by: Mengyuan Liu, et al.
Published: (2014-11-01)

Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's Coordinating Centers volunteers
by: Elizabeth A. Wise, et al.
Published: (2019-12-01)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
by: Yi-Ting Lin, et al.
Published: (2019-05-01)

CAN WE PREDICT THE RESPONSE TO GALANTAMINE IN ALZHEIMER`S DISEASE PATIENTS?
by: Carmen Gavan, et al.
Published: (2015-09-01)

Effekten av acetylkolinesterashämmare på patienter med indikation svår Alzheimers sjukdom
by: Sadrija, Valdete
Published: (2017)

Targeted Screening for Alzheimer's Disease Clinical Trials Using Data-Driven Disease Progression Models
by: Alexander, D.C, et al.
Published: (2022)

CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia
by: Chamnanphon M, et al.
Published: (2020-11-01)

Evaluation of the Adverse Effects of Chronic Exposure to Donepezil (An Acetylcholinesterase Inhibitor) in Adult Zebrafish by Behavioral and Biochemical Assessments
by: Gilbert Audira, et al.
Published: (2020-09-01)

Preparation and evaluation of novel galantamine hydrobromide sustained-release capsule
by: Shuoye Yang
Published: (2016-03-01)

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
by: Tariot Pierre, et al.
Published: (2012-06-01)

A Galantamine–Curcumin Hybrid Decreases the Cytotoxicity of Amyloid-Beta Peptide on SH-SY5Y Cells
by: Kirilka Mladenova, et al.
Published: (2021-07-01)

Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial
by: Hossein Pakdaman, et al.
Published: (2015-03-01)

Assessing the Safety of Cholinesterase Inhibitor Discontinuation in Patients with Moderate to Severe Alzheimer’s Disease in a Long Term Care Setting
by: O'Regan, Jordana
Published: (2014)

Assessing the Safety of Cholinesterase Inhibitor Discontinuation in Patients with Moderate to Severe Alzheimer’s Disease in a Long Term Care Setting
by: O'Regan, Jordana
Published: (2014)

Effect of donepezil and memantine on improvement of cognitive function in patients with temporal lobe epilepsy
by: Marjan Oustad, et al.
Published: (2020-01-01)

Effects of donepezil on behavioural manifestations of thalamic infarction: a single case observation
by: Rodrigo eRiveros, et al.
Published: (2011-03-01)